Germany · Delayed Price · Currency is EUR Scandinavian ChemoTech AB Statistics
Total Valuation
FRA:8V6 has a market cap or net worth of EUR 7.44 million. The enterprise value is 7.05 million.
| Market Cap | 7.44M |
| Enterprise Value | 7.05M |
Important Dates
The next estimated earnings date is Tuesday, March 3, 2026.
| Earnings Date | Mar 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 21.69M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +26.18% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 27.76% |
| Owned by Institutions (%) | 14.44% |
| Float | 14.42M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.05 |
| PB Ratio | 13.29 |
| P/TBV Ratio | 38.93 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -8.96 |
| EV / Sales | 6.63 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.17
| Current Ratio | 1.17 |
| Quick Ratio | 0.86 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.69 |
Financial Efficiency
Return on equity (ROE) is -114.78% and return on invested capital (ROIC) is -60.88%.
| Return on Equity (ROE) | -114.78% |
| Return on Assets (ROA) | -28.73% |
| Return on Invested Capital (ROIC) | -60.88% |
| Return on Capital Employed (ROCE) | -119.22% |
| Revenue Per Employee | 1.06M |
| Profits Per Employee | -786,832 |
| Employee Count | 6 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 0.59 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +123.24% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +123.24% |
| 50-Day Moving Average | 0.42 |
| 200-Day Moving Average | 0.22 |
| Relative Strength Index (RSI) | 29.79 |
| Average Volume (20 Days) | 11 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, FRA:8V6 had revenue of EUR 1.06 million and -786,832 in losses. Loss per share was -0.03.
| Revenue | 1.06M |
| Gross Profit | 867,785 |
| Operating Income | -667,798 |
| Pretax Income | -786,832 |
| Net Income | -786,832 |
| EBITDA | -655,949 |
| EBIT | -667,798 |
| Loss Per Share | -0.03 |
Balance Sheet
The company has 388,034 in cash and n/a in debt, giving a net cash position of 388,034.
| Cash & Cash Equivalents | 388,034 |
| Total Debt | n/a |
| Net Cash | 388,034 |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 560,162 |
| Book Value Per Share | 0.02 |
| Working Capital | 176,922 |
Cash Flow
| Operating Cash Flow | -964,115 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 82.15%, with operating and profit margins of -63.22% and -74.49%.
| Gross Margin | 82.15% |
| Operating Margin | -63.22% |
| Pretax Margin | -74.49% |
| Profit Margin | -74.49% |
| EBITDA Margin | -62.10% |
| EBIT Margin | -63.22% |
| FCF Margin | n/a |
Dividends & Yields
FRA:8V6 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -26.18% |
| Shareholder Yield | -26.18% |
| Earnings Yield | -10.57% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |